No genomic rearrangements by Southern blotting were seen in the brcAI candidate gene estradiol 17 beta dehydrogenase 2 (17hsd2), or in erbB2, prohibition (phb) and nmeI (previously nm23-HI).
However, several other factors, biological or time and patient dependent, influence the complex metastatic progression of ovarian tumors and may cooperate with nm23-H1 in the promotion or inhibition of this process.
Although this is a prospective study in which collection of clinical data is ongoing, the results strongly suggest that nm23-H1 may serve as a potentially valuable marker for ovarian tumors.
We have established that tumour progression in ovarian cancer is accompanied by over-expression of the NME1 gene; however, despite high rates of allele loss at the NME1 locus, the concept that NME1 may be a candidate tumour suppressor gene in ovarian cancercannot be confirmed by this study.
Immunohistochemistry performed on archival samples from ovarian carcinomas seems adequate for the demonstration of nm23 overexpression in ovarian cancer.
Effects of Per2 overexpression on growth inhibition and metastasis, and on MTA1, nm23-H1 and the autophagy-associated PI3K/PKB signaling pathway in nude mice xenograft models of ovarian cancer.